GLP-1 Receptor Activation Indirectly Reduces Hepatic Lipid Accumulation But Does Not Attenuate Development of Atherosclerosis in Diabetic Male ApoE−/− Mice
The DOI matches its Crossref record; 52 of the 53 references it cites were found in a registry or an index.
Abstract
Glucagon-like peptide-1 receptor (GLP-1R) agonists reduce lipid accumulation in peripheral tissues, attenuating atherosclerosis and hepatic steatosis in preclinical studies. We examined whether GLP-1R activation decreases atherosclerosis progression in high-fat diet-fed male ApoE(-/-) mice after administration of streptozotocin and treatment with the long-acting GLP-1R agonist taspoglutide administered once monthly vs. metformin in the drinking water for 12 wk. Taspoglutide did not reduce plaque area or lipid content in the aortic arch or abdominal aorta, and no significant change in aortic macrophage accumulation was detected after taspoglutide or metformin. In contrast, hepatic triglyceride levels were significantly reduced in livers from taspoglutide-treated mice. Both peripheral and intracerebroventricular administration of exendin-4 rapidly decreased plasma triglyceride levels in fasted mice, and taspoglutide therapy in ApoE(-/-) mice modulated the expression of hepatic genes controlling fatty acid uptake and oxidation. We were unable to detect expression of the entire Glp1r coding sequence in macrophages isolated from ApoE(-/-), C57BL/6, and IL10(-/-) mice. Similarly, Glp1r mRNA transcripts were not detected in RNA from isolated murine hepatocytes. Using Western blotting and tissue extracts from Glp1r(+/+) and Glp1r(-/-) mice, and cells transfected with a tagged murine GLP-1R cDNA, we could not validate the sensitivity and specificity of three different GLP-1R antisera commonly used for the detection of GLP-1R protein. Taken together, these findings illustrate divergent actions of GLP-1R agonists on atherosclerosis progression and accumulation of ectopic lipid in ApoE(-/-) mice and highlight the importance of indirect GLP-1R actions for the control of hepatic lipid accumulation.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Glp1r expression is undetectable by quantitative PCR in peritoneal or adipose tissue macrophages (37), although Lyz2-Cre–driven deletion of Glp1r (Glp1rLyz2–/–) abolishes expression in bone marrow–derived macrophages (38).”
From Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits (2025) · cites this paper as [37]
In the citing paper
“The limited specificity of many antibodies against mouse and human GLP-1R, combined with the challenges of detecting the receptor at low abundance, has been well documented (37, 39, 40).”
From Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits (2025) · cites this paper as [37]
Citations
Cites
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791 · cited 2×
“Histological sections were scored for hepatic lobular inflammation, ballooning, apoptosis, Kupffer cells, fibrosis, and steatosis according to guidelines set by the Pathology Committee of the NASH (nonalcoholic steatohepatitis) Clinical Research Network (25) in a blinded manner by a trained pathologist (C.”
Metabolism of Isolated Fat Cells
Rodbell, M. (1964) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)51687-2 · Cited by 4,427
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetologia · doi:10.1007/s00125-012-2534-0 · Cited by 3,919
Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetes Care · doi:10.2337/dc12-0413 · Cited by 3,207
The biology of incretin hormones
Drucker, D. J. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.01.004 · Cited by 2,210 · cited 1×
“Two of the relatively newer classes, glucagon-like peptide-1 receptor (GLP-1R) agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors, exert their glucose-lowering actions predominantly through activation of the GLP-1R (2).”
Self-citationMETABOLISM OF ISOLATED FAT CELLS. I. EFFECTS OF HORMONES ON GLUCOSE METABOLISM AND LIPOLYSIS.
Rodbell, M. (1964) · PubMed · Cited by 1,387
Insulin Resistance, Hyperglycemia, and Atherosclerosis
Bornfeldt, K. E., & Tabas, I. (2011) · Cell Metabolism · doi:10.1016/j.cmet.2011.07.015 · Cited by 995 · cited 3×
“Although hyperglycemia and insulin resistance substantially accelerate the development of clinical and experimental atherosclerosis (11), whether sustained activationofGLP-1Rsignalingmightattenuate thedevelopment of atherosclerosis in the setting of insulin resistance, impairment of -cell function, and hyperglycemia r…”
Scrocchi, L. A., Brown, T. J., Maclusky, N., Brubaker, P. L., Auerbach, A. B., Joyner, A. L., & Drucker, D. J. (1996) · Nature Medicine · doi:10.1038/nm1196-1254 · Cited by 793 · cited 6×
“D PBO (14) D Met PBO (15) D TASPO (15) * * ** ***”
InfluentialSelf-citationTissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor
Bullock, B. P., Heller, R. S., & Habener, J. F. (1996) · Endocrinology · doi:10.1210/en.137.7.2968 · Cited by 618 · cited 2×
“In contrast, other investigators have failed to detect mRNA transcripts encoding a full-length Glp1r in human, rat, or mouse liver (17, 37, 47-49), and we previously reported the absence of cAMP accumulation in response to GLP-1 or exendin-4 in isolated murine hepatocytes (17).”
Noyan-Ashraf, M. H., Momen, M. A., Ban, K., Sadi, A.-M., Zhou, Y.-Q., Riazi, A. M., Baggio, L. L., Henkelman, R. M., Husain, M., & Drucker, D. J. (2009) · Diabetes · doi:10.2337/db08-1193 · Cited by 575 · cited 1×
“ocytes and exert direct effects in the cardiovascular system (3).”
Self-citation
Cited by
Items 101–200 of 346
Farr, S., Baker, C., Naples, M., Taher, J., Iqbal, J., Hussain, M., & Adeli, K. (2015) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.114.304873 · Cited by 61
“This finding is reminiscent of decreased hepatic lipid content in DPP-4–deficient rats(34) and high-fat– fed apoE mice treated with the GLP-1R agonist taspoglutide.(35) Reductions in jejunal MTP activity may be secondary to this initial decrease in lipid substrate.”
BackgroundResultPhysiology and pathophysiology of incretins in the kidney
von Websky, K., Reichetzeder, C., & Hocher, B. (2013) · Current Opinion in Nephrology & Hypertension · doi:10.1097/01.mnh.0000437542.77175.a0 · Cited by 68
“The data about DPP-4 and GLP-1R expression in the kidney are still incomplete and speculation of low specificity and sensitivity of existing antibodies gives reason for the discussion about the validity of immunostaining data [30,31].”
BackgroundMarlet, I. R., Ölmestig, J. N. E., Vilsbøll, T., Rungby, J., & Kruuse, C. (2018) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.12974 · Cited by 61
Obesity, diabetes, and inflammation: Pathophysiology and clinical implications
Donath, M. Y., & Drucker, D. J. (2025) · Immunity · doi:10.1016/j.immuni.2025.09.011 · Cited by 69
Self-citationGLP-1 based therapies: clinical implications for gastroenterologists
Smits, M. M., van Raalte, D. H., Tonneijck, L., Muskiet, M. H. A., Kramer, M. H. H., & Cahen, D. L. (2016) · Gut · doi:10.1136/gutjnl-2015-310572 · Cited by 61
“144 145 In addition, GLP-1 in fl uences bile metabolism.”
BackgroundTakai, A., Kikuchi, K., Ichimura‐Shimizu, M., Tsuneyama, K., Moritoki, Y., Matsumoto, K., Tsunashima, H., Onda, T., Kuniyoshi, N., Nariyama, T., et al. (2020) · BMC Gastroenterology · doi:10.1186/s12876-020-01194-2 · Cited by 67
Gotfredsen, C. F., Mølck, A.-M., Thorup, I., Nyborg, N. C. B., Salanti, Z., Knudsen, L. B., & Larsen, M. O. (2014) · Diabetes · doi:10.2337/db13-1087 · Cited by 60
“Within GLP-1RAs, differences exist in safety-related parameters.”
BackgroundInfluentialNaylor, J., Suckow, A. T., Seth, A., Baker, D. J., Sermadiras, I., Ravn, P., Howes, R., Li, J., Snaith, M. R., Coghlan, M. P., et al. (2016) · Biochemical Journal · doi:10.1042/bcj20160476 · Cited by 60
Exploring the effects of DPP-4 inhibitors on the kidney from the bench to clinical trials
Coppolino, G., Leporini, C., Rivoli, L., Ursini, F., Paola, E. D. D., Cernaro, V., Arturi, F., Bolignano, D., Russo, E., Sarro, G. D., et al. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.12.001 · Cited by 64
“GLP-1 has been lso reported to modulate hepatic lipid metabolism by suppressng fatty acid synthesis and promoting fatty acid oxidation [88,89].”
Chang, W., Zhu, F., Zheng, H., Zhou, Z., Miao, P., Zhao, L., & Mao, Z. (2019) · Molecular Immunology · doi:10.1016/j.molimm.2019.09.021 · Cited by 60
Jouihan, H., Will, S., Guionaud, S., Boland, M. L., Oldham, S., Ravn, P., Celeste, A., & Trevaskis, J. L. (2017) · Molecular Metabolism · doi:10.1016/j.molmet.2017.09.001 · Cited by 59
“of a functional GLP-1R on human hepatocytes [28], although a comprehensive analysis suggests that full-length GLP-1R mRNA is not present in hepatocytes or macrophages [29].”
BackgroundThomas, M. C., Coughlan, M. T., & Cooper, M. E. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2023.01.004 · Cited by 56
Prevention of Obesity-Induced Renal Injury in Male Mice by DPP4 Inhibition
Nistala, R., Habibi, J., Lastra, G., Manrique, C. M., Aroor, A. R., Hayden, M. R., Garro, M., Meuth, A. I., Johnson, M. S., Whaley‐Connell, A. T., et al. (2014) · Endocrinology · doi:10.1210/en.2013-1920 · Cited by 63
Pandey, S., Mangmool, S., & Parichatikanond, W. (2023) · Pharmaceuticals · doi:10.3390/ph16060836 · Cited by 56
“GLP-1R expresses in various immune cells, including splenocytes, thymocytes, regulatory T cells, bone marrow-derived cells, macrophages, and invariant natural killer T cells, and thereby modulates the immune responses [60,61].”
BackgroundYang, S.-H., Xu, R.-X., Cui, C.-J., Wang, Y., Du, Y., Chen, Z.-G., Yao, Y.-H., Ma, C.-Y., Zhu, C.-G., Guo, Y.-L., et al. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-018-0689-9 · Cited by 56
GLP-1 and Underlying Beneficial Actions in Alzheimer’s Disease, Hypertension, and NASH
Li, Q.-X., Gao, H., Guo, Y.-X., Wang, B.-Y., Hua, R.-X., Gao, L., Shang, H.-W., Lu, X., & Xu, J.-D. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.721198 · Cited by 56
Duca, F. A., Bauer, P. V., Hamr, S. C., & Lam, T. K. T. (2015) · Cell Metabolism · doi:10.1016/j.cmet.2015.07.003 · Cited by 64
“…of GLP-1R protein in the portal vein has been documented, but the specificity of the antibody was not properly established (Vahl et al., 2007; Panjwani et al., 2013), thus questioning whether GLP-1R in the nodose ganglia is actually transported to the afferent terminals innervating the…”
Furuhashi, M., Hiramitsu, S., Mita, T., Fuseya, T., Ishimura, S., Omori, A., Matsumoto, M., Watanabe, Y. S., Hoshina, K., Tanaka, M., et al. (2015) · Journal of Lipid Research · doi:10.1194/jlr.m059469 · Cited by 58
Inventing Liraglutide, a Glucagon-Like Peptide-1 Analogue, for the Treatment of Diabetes and Obesity
Knudsen, L. B. (2019) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.9b00048 · Cited by 56
Hirano, T., & Mori, Y. (2016) · Journal of Diabetes Investigation · doi:10.1111/jdi.12446 · Cited by 55
“In U937 human monocytes, the active form of the incretin receptor agonists, Ex-4, GIP(1-42), and D-(Ala2) GIP, elicited cAMP generation, whereas the inactive form, GLP-1(9-36)amide and GIP (3-42), did not, suggesting that the incretins’ signal enters monocytes through classical incretin receptors.”
BackgroundSudo, M., Li, Y., Hiro, T., Takayama, T., Mitsumata, M., Shiomi, M., Sugitani, M., Matsumoto, T., Hao, H., & Hirayama, A. (2017) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2017.06.920 · Cited by 56
Andersen, D. B., Grunddal, K. V., Pedersen, J., Kuhre, R. E., Lund, M. L., Holst, J. J., & Ørskov, C. (2021) · Endocrinology · doi:10.1210/endocr/bqaa246 · Cited by 54
Vergès, B., Duvillard, L., Pais de Barros, J. P., Bouillet, B., Baillot-Rudoni, S., Rouland, A., Petit, J. M., Degrace, P., & Demizieux, L. (2021) · Diabetes Care · doi:10.2337/dc20-1843 · Cited by 54
Dhir, G., & Cusi, K. (2018) · Journal of Investigative Medicine · doi:10.1136/jim-2017-000554 · Cited by 53
Incretin actions beyond the pancreas: lessons from knockout mice
Yabe, D., & Seino, Y. (2013) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2013.09.013 · Cited by 57
Liraglutide Decreases Hepatic Inflammation and Injury in Advanced Lean Non‐Alcoholic Steatohepatitis
Ipsen, D. H., Rolin, B., Rakipovski, G., Skovsted, G. F., Madsen, A., Kolstrup, S. H., Schou‐Pedersen, A. M. V., Skat‐Rørdam, J., Lykkesfeldt, J., & Tveden‐Nyborg, P. (2018) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.13082 · Cited by 59
Pang, J., Feng, J. N., Ling, W., & Jin, T. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.06.003 · Cited by 52
“Several studies have shown the detection of Glp1r mRNA and GLP-1R protein in mouse or human hepatic cell lines and the mouse liver107,116,117, in contrast to the early report by Bullock et al.114 Investigations by Panjwani et al.105 and by Baggio et al.106 showed that the controversy could be partially due to the lack…”
MethodDPP-4 inhibitors in diabetic complications: role of DPP-4 beyond glucose control
Bae, E. J. (2016) · Archives of Pharmacal Research · doi:10.1007/s12272-016-0813-x · Cited by 62
“GLP-1R mRNA transcripts have been detected in the human liver by RT-PCR and an immunoreactive GLP-1R protein was detected in murine, rat, and human hepatocytes by western blotting (Ding et al. 2006; Gupta et al. 2010; Panjwani et al. 2013; SvegliatiBaroni et al. 2011).”
BackgroundYang, M., Fukui, H., Eda, H., Xu, X., Kitayama, Y., Hara, K., Kodani, M., Tomita, T., Oshima, T., Watari, J., et al. (2017) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00232.2016 · Cited by 52
“On the other hand, the immunohistochemical localization of GLP-1R in the GI tract remains to be reconfirmed because the specificity of available anti-GLP-1R antibodies is debatable (24).”
BackgroundCariou, B. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14651 · Cited by 62
“In the one hand, several studies concluded that GLP1R is not expressed at significant levels in the hepatocytes.(88,89) On the other”
BackgroundMoberly, S. P., Mather, K. J., Berwick, Z. C., Owen, M. K., Goodwill, A. G., Casalini, E. D., Hutchins, G. D., Green, M. A., Ng, Y., Considine, R. V., et al. (2013) · Basic Research in Cardiology · doi:10.1007/s00395-013-0365-x · Cited by 51
“And finally, as noted above, although the current observations suggest that differences in myocardial expression of the GLP-1 receptor do not explain the observed differential responses, the available tools for immunologic detection of the GLP-1 receptor are currently being re-evaluated [4, 32, 36], which prevents def…”
InfluentialKhound, R., Taher, J., Baker, C., Adeli, K., & Su, Q. (2017) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.117.310251 · Cited by 51
Antidiabetic Drugs in NAFLD: The Accomplishment of Two Goals at Once?
Tacelli, M., Celsa, C., Magro, B., Giannetti, A., Pennisi, G., Spatola, F., & Petta, S. (2018) · Pharmaceuticals · doi:10.3390/ph11040121 · Cited by 51
Ceddia, R. P., & Collins, S. (2020) · Clinical Science · doi:10.1042/cs20190579 · Cited by 53
Zhang, H., Liu, Y., Guan, S., Qu, D., Wang, L., Wang, X., Li, X., Zhou, S., Zhou, Y., Wang, N., et al. (2016) · PLOS ONE · doi:10.1371/journal.pone.0148827 · Cited by 50
Impact of exenatide on mitochondrial lipid metabolism in mice with nonalcoholic steatohepatitis
Kalavalapalli, S., Bril, F., Guingab, J., Vergara, A., Garrett, T. J., Sunny, N. E., & Cusi, K. (2019) · Journal of Endocrinology · doi:10.1530/joe-19-0007 · Cited by 48
Cherney, D. Z. I., Udell, J. A., & Drucker, D. J. (2021) · Med · doi:10.1016/j.medj.2021.10.004 · Cited by 50
Self-citationYamazaki, S., Satoh, H., & Watanabe, T. (2014) · Endocrinology · doi:10.1210/en.2013-2157 · Cited by 49
Kushima, H., Mori, Y., Koshibu, M., Hiromura, M., Kohashi, K., Terasaki, M., Fukui, T., & Hirano, T. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0603-x · Cited by 48
Vessey, K. A., Jobling, A. I., Tran, M. X., Wang, A. Y., Greferath, U., & Fletcher, E. L. (2022) · Autophagy · doi:10.1080/15548627.2022.2034131 · Cited by 49
Antidiabetic Agents and Endothelial Dysfunction – Beyond Glucose Control
Eriksson, L., & Nyström, T. (2015) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.12402 · Cited by 52
Liu, D., Pang, J., Shao, W., Gu, J., Zeng, Y., He, H. H., Ling, W., Qian, X., & Jin, T. (2021) · Hepatology · doi:10.1002/hep.31856 · Cited by 48
Schwenk, R. W., Baumeier, C., Finan, B., Kluth, O., Brauer, C., Joost, H.-G., DiMarchi, R. D., Tschöp, M. H., & Schürmann, A. (2015) · Diabetologia · doi:10.1007/s00125-014-3478-3 · Cited by 46
“This is opposite to the findings in the hypothalamus and similar to that in pancreatic islets, and could be explained by the lack of GLP-1 receptor expression in these tissues [31, 32].”
ResultTang, S.-T., Zhang, Q., Tang, H.-Q., Wang, C.-J., Su, H., Zhou, Q., Wei, W., Zhu, H.-Q., & Wang, Y. (2016) · Endocrine · doi:10.1007/s12020-015-0852-y · Cited by 46
Intra-islet glucagon-like peptide 1
Fava, G. E., Dong, E. W., & Wu, H. (2016) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2016.05.016 · Cited by 45
Le, T. D. V., Fathi, P. A., Watters, A. B., Ellis, B. J., Besing, G.-L. K., Bozadjieva-Kramer, N., Perez, M. B., Sullivan, A. I., Rose, J. P., Baggio, L. L., et al. (2023) · Molecular Metabolism · doi:10.1016/j.molmet.2023.101718 · Cited by 50
Self-citationDirect cardiovascular effects of glucagon like peptide-1
Sheikh, A. (2013) · Diabetology & Metabolic Syndrome · doi:10.1186/1758-5996-5-47 · Cited by 45
“Taspoglutide (a long acting GLP-1 agonist) was not found to have significant anti-atheromatous effects, although it did reduce hepatic triglyceride levels, suggesting an indirect mode of action [97].”
BackgroundThe endogenous preproglucagon system is not essential for gut growth homeostasis in mice
Wismann, P., Barkholt, P., Secher, T., Vrang, N., Hansen, H. B., Jeppesen, P. B., Baggio, L. L., Koehler, J. A., Drucker, D. J., Sandoval, D. A., et al. (2017) · Molecular Metabolism · doi:10.1016/j.molmet.2017.04.007 · Cited by 43
Self-citationSoto‐Catalán, M., Opazo-Ríos, L., Quiceno, H., Lázaro, I., Moreno, J. A., Gómez‐Guerrero, C., Egido, J., & Mas, S. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25052961 · Cited by 51
“Although the presence of the GLP-1 receptor in the liver remains controversial, GLP-1 has demonstrated an indirect hepatoprotective effect via the gut–pancreas–liver axis [15,16].”
BackgroundIncretin-Based Therapy for Prevention of Diabetic Vascular Complications
Mima, A. (2015) · Journal of Diabetes Research · doi:10.1155/2016/1379274 · Cited by 48
Khalifa, O., AL-Akl, N. S., Errafii, K., & Arredouani, A. (2022) · Scientific Reports · doi:10.1038/s41598-022-06143-5 · Cited by 42
Ip, W., Shao, W., Chiang, Y.-T. A., & Jin, T. (2013) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00376.2013 · Cited by 43
“(fo ld , n or m al iz ed to C R E B ) Vehicle FSK GLP-1(28-36)a”
BackgroundInfluentialDecara, J., Arrabal, S., Beiroa, D., Rivera, P., Vargas, A., Serrano, A., Pavón, F. J., Ballesteros, J., Dieguez, C., Nogueiras, R., et al. (2016) · BioFactors · doi:10.1002/biof.1295 · Cited by 42
Shao, S., Zhang, X., Xu, Q., Pan, R., & Chen, Y. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108270 · Cited by 46
Heinonen, S. E., Genové, G., Bengtsson, E., Hübschle, T., Åkesson, L., Hiss, K., Benardeau, A. M., Ylä‐Herttuala, S., Jönsson‐Rylander, A., & Gomez, M. F. (2015) · Journal of Diabetes Research · doi:10.1155/2015/404085 · Cited by 44
“One study using the glucagon-like peptide 1 (GLP-1) analog taspoglutide reported improvement of diabetic parameters and reduced hepatic lipid accumulation but no effects on atherosclerosis [91].”
Central nervous system regulation of hepatic lipid and lipoprotein metabolism
Taher, J., Farr, S., & Adeli, K. (2016) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000373 · Cited by 56
Vergès, B. L., & Charbonnel, B. H. (2017) · Diabetes & Metabolism · doi:10.1016/s1262-3636(17)30067-8 · Cited by 44
Fluorescent exendin-4 derivatives for pancreatic β-cell analysis
Clardy, S. M., Keliher, E. J., Mohan, J. F., Sebas, M., Benoist, C., Mathis, D., & Weissleder, R. (2014) · Bioconjugate Chemistry · doi:10.1021/bc4005014 · Cited by 41
Maiseyeu, A., Di, L., Ravodina, A. M., Barajas‐Espinosa, A. R., Sakamoto, A., Chaplin, A. M. L., Zhong, J., Gao, H., Mignery, M., Narula, N., et al. (2022) · Theranostics · doi:10.7150/thno.66456 · Cited by 43
“Importantly, examining full-length Glp1r mRNA encoding for GLP-1R open reading frame remains the only reliable method for investigation of the Glp1r expression in rodent tissues and cells, as many commercially available antibodies proved to be non-specific [5,6].”
BackgroundPetrovic, A., Igrec, D., Rozac, K., Bojanic, K., Kuna, L., Kolaric, T. O., Mihaljevic, V., Sikora, R., Smolic, R., Glasnovic, M., et al. (2023) · Current Issues in Molecular Biology · doi:10.3390/cimb45060288 · Cited by 41
“However, due to the conflicting results of similar studies [19], possibly because of technical differences [20], there is an ongoing debate on the presence of GLP-1R on hepatocytes.”
BackgroundAbility of GLP-1 to decrease food intake is dependent on nutritional status
Ronveaux, C. C., de Lartigue, G., & Raybould, H. E. (2014) · Physiology & Behavior · doi:10.1016/j.physbeh.2014.06.015 · Cited by 41
“Panjwani et al [33] have suggested that GLP-1R antibody is not specific as an immunoreactive band was observed in tissue from GLP-1R knockout mice.”
BackgroundThe interplay between nonalcoholic fatty liver disease and atherosclerotic cardiovascular disease
Finney, A. C., Das, S., Kumar, D., McKinney, M. P., Cai, B., Yurdagul, A., & Rom, O. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1116861 · Cited by 40
GLP1R and GIPR expression and signaling in pancreatic alpha cells, beta cells and delta cells
Shilleh, A. H., Viloria, K., Broichhagen, J., Campbell, J. E., & Hodson, D. J. (2024) · Peptides · doi:10.1016/j.peptides.2024.171179 · Cited by 39
Self-citationInsights into incretin-based therapies for treatment of diabetic dyslipidemia
Stemmer, K., Finan, B., DiMarchi, R. D., Tschöp, M. H., & Müller, T. D. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.05.008 · Cited by 43
Discordance between GLP-1R gene and protein expression in mouse pancreatic islet cells
Gray, S. M., Xin, Y., Ross, E. C., Chazotte, B. M., Capozzi, M. E., El, K., Svendsen, B., Ravn, P., Sloop, K. W., Tong, J., et al. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.ra120.014368 · Cited by 38
Self-citationThe Vicious Circle of Hepatic Glucagon Resistance in Non-Alcoholic Fatty Liver Disease
Galsgaard, K. D. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9124049 · Cited by 43
Application of glucagon-like peptide-1 receptor antagonists in fibrotic diseases
Yang, F., Luo, X., Li, J., Yu, L., Zeng, F., Huang, X., Lan, Y., & Liu, R. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113236 · Cited by 44
The Identification of Novel Proteins That Interact With the GLP-1 Receptor and Restrain its Activity
Huang, X., Dai, F. F., Gaisano, G., Giglou, K., Han, J., Zhang, M., Kittanakom, S., Wong, V., Li, W., Showalter, A. D., et al. (2013) · Molecular Endocrinology · doi:10.1210/me.2013-1047 · Cited by 45
Editorial: Antibody Validation Requirements for Articles Published in Endocrinology
Gore, A. C. (2013) · Endocrinology · doi:10.1210/en.2012-2222 · Cited by 38
Incretin combination therapy for the treatment of non-alcoholic steatohepatitis
Kannt, A., Madsen, A. N., Kammermeier, C., Elvert, R., Klöckener, T., Bossart, M., Haack, T., Evers, A., Lorenz, K., Hennerici, W., et al. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14035 · Cited by 37
Development and characterisation of a novel glucagon like peptide-1 receptor antibody
Biggs, E. K., Liang, L., Naylor, J., Madalli, S., Collier, R., Coghlan, M. P., Baker, D. J., Hornigold, D. C., Ravn, P., Reimann, F., et al. (2018) · Diabetologia · doi:10.1007/s00125-017-4491-0 · Cited by 37
“When considering GLP1R expression, the field of research has been limited by a lack of specificity of commercially available GLP1R antibodies [3].”
BackgroundGlucagon‐Like Peptide‐1: Actions and Influence on Pancreatic Hormone Function
Davis, E., & Sandoval, D. A. (2020) · Comprehensive physiology · doi:10.1002/cphy.c190025 · Cited by 59
Zhou, W., Shao, W., Zhang, Y., Liu, D., Liu, M., & Jin, T. (2020) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00292.2020 · Cited by 36
Byrd, R. A., Sorden, S. D., Ryan, T., Pienkowski, T., LaRock, R., Quander, R., Wijsman, J. A., Smith, H. W., Blackbourne, J. L., Rosol, T. J., et al. (2015) · Endocrinology · doi:10.1210/en.2014-1722 · Cited by 36
“Some uncertainty remains regarding the specificity of the antibodies available for detection of the GLP-1 receptor (31, 32).”
Incretin drugs as modulators of atherosclerosis
Gallego-Colon, E., Wojakowski, W., & Francuz, T. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.09.011 · Cited by 35
Hansen, H. H., Pors, S. E., Andersen, M. W., Vyberg, M., Nøhr-Meldgaard, J., Nielsen, M. H., Oró, D., Madsen, M. R., Lewińska, M., Møllerhøj, M. B., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-50328-5 · Cited by 42
Arredouani, A. (2025) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2025.108824 · Cited by 36
GLP-1 receptor independent pathways: emerging beneficial effects of GLP-1 breakdown products
Guglielmi, V., & Sbraccia, P. (2016) · Eating and Weight Disorders - Studies on Anorexia Bulimia and Obesity · doi:10.1007/s40519-016-0352-y · Cited by 42
Lyu, J., Imachi, H., Fukunaga, K., Sato, S., Kobayashi, T., Dong, T., Saheki, T., Matsumoto, M., Iwama, H., Zhang, H., et al. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2019.12.015 · Cited by 36
“Because mature antibody is unable to recognize GLP-1R protein and to detect the full length of GLP-1R mRNA, the expression of GLP-1R in hepatocytes is controversial [47].”
BackgroundKedees, M. H., Guz, Y., Grigoryan, M., & Teitelman, G. (2013) · Peptides · doi:10.1016/j.peptides.2013.07.022 · Cited by 40
Zhang, Y., Gao, S., Liang, K., Wu, Z., Yan, X., Liu, W., Li, J., Wu, B., & Du, Y. (2021) · Science Advances · doi:10.1126/sciadv.abi4379 · Cited by 41
Evidence for the existence and potential roles of intra-islet glucagon-like peptide-1
Campbell, S. A., Johnson, J., & Light, P. E. (2021) · Islets · doi:10.1080/19382014.2021.1889941 · Cited by 42
Time for Glucagon like peptide-1 receptor agonists treatment for patients with NAFLD?
Gastaldelli, A., & Marchesini, G. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.11.031 · Cited by 38
“In vitro and in vivo studies in experimental animals reported a decrease in hepatic fat with the short-acting exenatide treatment, associated with improved hepatic lipid metabolism, namely lipid oxidation [1,5–8].”
BackgroundHepatokines and MASLD: The GLP1-Ras-FGF21-Fetuin-A Crosstalk as a Therapeutic Target
Milani, I., Codini, M., Guarisco, G., Chinucci, M., Gaita, C., Leonetti, F., & Capoccia, D. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms251910795 · Cited by 44
“Regarding the localization of the GLP-1R in the liver, some studies suggest the absence of GLP-1 receptors in hepatocytes [115,116], while others indicate their presence [117–120].”
BackgroundGonzalez-Rellan, M. J., Riobello, C., Fang, S., da Silva, E. M., Koehler, J. A., Shang, R., Hammoud, R., Cao, X., Varela‐Rey, M., & Drucker, D. J. (2026) · Cell Metabolism · doi:10.1016/j.cmet.2026.03.011 · Cited by 47
Self-citationJun, L. S., Showalter, A. D., Ali, N., Dai, F., Ma, W., Coskun, T., Ficorilli, J. V., Wheeler, M. B., Michael, M. D., & Sloop, K. W. (2014) · PLoS ONE · doi:10.1371/journal.pone.0093746 · Cited by 32
Boland, B. B., Laker, R. C., O'Brien, S., Sitaula, S., Sermadiras, I., Nielsen, J. C., Barkholt, P., Roostalu, U., Hecksher‐Sørensen, J., Sejthen, S. R., et al. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101392 · Cited by 43
“As neither Y2R nor GLP1R are expressed by skeletal muscle or the liver [53,54], the effect of Fc-PYY3-36 þ Fc-GLP-1 combination on peripheral and hepatic insulin sensitization must be secondary.”
BackgroundTate, M., Chong, A., Robinson, E., Green, B. D., & Grieve, D. J. (2015) · British Journal of Pharmacology · doi:10.1111/bph.12943 · Cited by 33
“…to atrial tissue, sinoatrial node and vasculature, with some species variation (Kim et al., 2013; Pyke et al., 2014; Richards et al., 2014), and that earlier reports of more ubiquitous expression may be questionable because of poor antibody selectivity and sensitivity (Panjwani et al., 2012).”
BackgroundTatarkiewicz, K., Sablan, E. J., Polizzi, C. J., Villescaz, C., & Parkes, D. G. (2014) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00495.2013 · Cited by 31
“The direct and indirect mechanisms underlying these effects have not been fully elucidated, and there is still limited and controversial knowledge regarding GLP-1R distribution in different tissues and different species (33).”
BackgroundPiro, S., Mascali, L. G., Urbano, F., Filippello, A., Malaguarnera, R., Calanna, S., Rabuazzo, A. M., & Purrello, F. (2014) · PLoS ONE · doi:10.1371/journal.pone.0090093 · Cited by 37
“Although at the present time there is currently no known specific GLP-1R antibody that detects authentic GLP-1R protein [46,47], we clearly found not only GLP-1R (protein and mRNA transcript) but also distinct biologic effects, such as the increase in cAMP levels and the inhibition of the release of glucagon.”
BackgroundAn Analysis of Characteristics of Subjects Examined for Incretin Effects on Pancreatic Pathology
Harja, E., Lord, J., & Skyler, J. S. (2013) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2013.0177 · Cited by 30
“failed to note that there is controversy as to whether GLP-1 receptors are expressed in such tissues, depending on which antibody is used to measure GLP-1 receptors, with multiple GLP-1 receptor antibodies, including several used to localize GLP-1 receptor expression in the pancreas, failing to exhibit appropriate sen…”
Zhang, N., Tao, J., Gao, L., Bi, Y., Li, P., Wang, H., Zhu, D., & Feng, W. (2020) · BioMed Research International · doi:10.1155/2020/2947549 · Cited by 31
Molecular chaperones and G protein-coupled receptor maturation and pharmacology
Tao, Y. (2020) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2020.110862 · Cited by 33
Shah, F. A., Mahmud, H., Gallego‐Martin, T., Jurczak, M. J., O'Donnell, C. P., & McVerry, B. J. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2019-00296 · Cited by 33
Repositioning the Alpha Cell in Postprandial Metabolism
EL, K. M., Capozzi, M. E., & Campbell, J. E. (2020) · Endocrinology · doi:10.1210/endocr/bqaa169 · Cited by 37
“The GCGR is also highly expressed in the liver (68), while the GLP-1R is not (82).”
BackgroundSelf-citationGLP-1 mimetics as a potential therapy for nonalcoholic steatohepatitis
Chen, Y., Xu, Y.-N., Ye, C.-Y., Feng, W., Zhou, Q., Yang, D., & Wang, M. (2021) · Acta Pharmacologica Sinica · doi:10.1038/s41401-021-00836-9 · Cited by 34
Structural insight into antibody-mediated antagonism of the Glucagon-like peptide-1 Receptor
Hennen, S., Kodra, J. T., Soroka, V., Krogh, B. O., Wu, X., Kaastrup, P., Ørskov, C., Rønn, S. G., Schluckebier, G., Barbateskovic, S., et al. (2016) · Scientific Reports · doi:10.1038/srep26236 · Cited by 33
“The binding properties of mAb 3F52 to GLP-1R were characterized in a competition binding assay using 125I-GLP-1(7-37)-OH as the tracer on cell membranes expressing the human GLP-1R.”
InfluentialMulvihill, E. E. (2018) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000495 · Cited by 29
Self-citationGLP-1R activation for the treatment of stroke: Updating and future perspectives
Darsalia, V., Nathanson, D., Nyström, T., Klein, T., Sjöholm, Å., & Patrone, C. (2014) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-014-9285-9 · Cited by 31
Podewin, T., Ast, J., Broichhagen, J., Fine, N. H. F., Nasteska, D., Leippe, P., Gailer, M., Buenaventura, T., Kanda, N., Jones, B. J., et al. (2018) · ACS Central Science · doi:10.1021/acscentsci.7b00237 · Cited by 34
Metadata
- Authors
- Panjwani, N., Mulvihill, E. E., Longuet, C., Yusta, B., Campbell, J. E., Brown, T. J., Streutker, C., Holland, D., Cao, X., Baggio, L. L., & Drucker, D. J.
- Affiliations
- Mount Sinai Hospital (CA)
- St. Michael's Hospital (CA)
- Corresponding author
- Drucker, Daniel J.
- ORCID
- Venue
- Endocrinology
- Publisher
- The Endocrine Society
- Published
- 2013-01-01
- Volume
- 154
- Issue
- 1
- Pages
- 127-139
- ISSN
- 0013-7227 (ISSN-L)
- 1945-7170
- OpenAlex
- W1992116679
- Cited by
- 346
- References
- 53
- Citations by year
- 2026: 12 · 2025: 19 · 2024: 19 · 2023: 23 · 2022: 23 · 2021: 21 · 2020: 24 · 2019: 23 · 2018: 27 · 2017: 24 · 2016: 26 · 2015: 32 · 2014: 38 · 2013: 32
- FWCI
- 26.42
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Endocrinology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Canadian Institutes of Health Research
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- GLP-1 receptor, exendin-4, atherosclerosis, hepatic lipid accumulation, hepatic steatosis, ApoE-deficient mice, streptozotocin-induced diabetes, metformin, aortic plaque, hepatic triglycerides, fatty acid uptake, fatty acid oxidation
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Animals, Apolipoproteins E, Body Composition, Glucose Tolerance Test, Liver, Macrophages, Male, Peptides, Blotting, Western, Interleukin-10, Receptors, Glucagon, Mice, Knockout, Hepatocytes, Atherosclerosis, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.